



April 24, 2023

To,  
Listing/ Compliance Department  
**BSE LTD.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**SCRIP CODE: 543748**

To,  
Listing/ Compliance Department  
**National Stock Exchange of  
India Limited**  
"Exchange Plaza", Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**SYMBOL: AARTIPHARM**

Dear Sir/Madam,

**Sub: Reporting of Initial Disclosure to be made by entities identified  
as Large Corporates**

Pursuant to SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 ('Circular') dated August 10, 2021 (updated as on April 13, 2022), we hereby confirm that the Company is not identified as Large Corporates (LC) as per the criteria in the said Circular, for the Financial Year ended March 31, 2023.

Further, we are enclosing herewith **Annexure-A** as required under the aforesaid circular.

Please take the same on your records.

Thanking You,

Yours faithfully,  
**For AARTI PHARMALABS LIMITED**  
(Formerly known as Aarti Organics Limited)

NIKHIL  
PANDURAN  
G NATU

Digitally signed by  
NIKHIL PANDURANG  
NATU  
Date: 2023.04.24  
18:13:42 +05'30'

NIKHIL NATU  
**COMPANY SECRETARY**  
ICSI M. NO. A27738

Encl.: a/a.

**AARTI PHARMALABS LIMITED**

**www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com**

**Admin Office :** 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234  
**Regd. Office :** Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

## Annexure A

### Initial disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1.	Name of the Company	Aarti Pharmalabs Ltd
2.	CIN	L24100GJ2019PLC110964
3.	Outstanding borrowing of the Company as on 31st March, 2023 (in Rs. crore)	There are no long-term borrowings in the Company as on 31st March, 2023
4.	Highest credit rating during the previous financial year along with name of the credit rating agency	Not Applicable
5.	Name of Stock Exchange* in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not Applicable

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 (updated as on April 13, 2022).

#### For AARTI PHARMALABS LIMITED

(Formerly known as Aarti Organics Limited)

NIKHIL  
PANDURA  
NG NATU

Digitally signed by  
NIKHIL  
PANDURANG NATU  
Date: 2023.04.24  
18:14:05 +05'30'

NIKHIL NATU  
**COMPANY SECRETARY**  
ICSI M. NO. A27738  
Contact No.: 02267976666

PIYUSH  
PRAVIN  
LAKHANI

Digitally signed by  
PIYUSH PRAVIN  
LAKHANI  
Date: 2023.04.24  
18:12:44 +05'30'

PIYUSH LAKHANI  
**CHIEF FINANCIAL OFFICER**  
Contact No.: 02267976666

Date: April 24, 2023

*\*In terms paragraph of 2.2(d) of the circular, beginning FY2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of stock exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.*